Unvaccinated virus patients 4 times more likely to develop myocarditis than fully-jabbed people; health expert says findings underline vaccine's importance as Israel comes to grips with mounting morbidity
Clalit: Pfizer vaccine cuts symptomatic infections 94%
Research analyzing data from 1.2 million Israelis has corroborated the high efficacy in Pfizer s clinical trials.
Israel s Clalit Health Services Research Institute has published its first research paper on the efficacy of the Covid-19 vaccinations and their influence on preventing infection and morbidity in all age groups.
Clalit, Israel s largest health maintenance organization (HMO) analyzed data from 1.2 million members - 600,000 members who received the Pfizer vaccination and 600,000 members with a similar profile who were not vaccinated. The research found that there was a 94% fall in symptomatic infections among those who were vaccinated and a 92% fall in the rate of those who were seriously ill with Covid-19 among the 600,000 who were vaccinated, compared with the 600,000 who did not receive any vaccination. The efficacy was seen in all age groups, including over 70s, who were only represented in a limited group in Pfi
Pfizer vaccine reduces rate of symptomatic infections by 94%, research shows
Study also shows that a week after receiving the second dose, the vaccine is 91-99% efficient in preventing the pathogen from evolving into a serious illness; results expected to become much more accurate as time passes and as more Israelis pass the-two week benchmark after second jab
Adir Yanko, Yaron Druckman |
Published: 02.14.21 , 22:10
Research conducted by the Clalit Health Fund released Sunday shows that Pfizer’s coronavirus vaccine is exceptionally effective in preventing infection and severe illness in all age groups, including those aged 70 and over.
The study includes data on some 1.2 million Israelis insured by Clalit, of whom about 600,000 have received both doses of the Pfizer’s vaccine.